All Pain, No GAIN: Need for Prudent Antimicrobial Use Provisions to Complement the GAIN Act by Outterson, Kevin
Boston University School of Law
Scholarly Commons at Boston University School of Law
Faculty Scholarship
Spring 2012
All Pain, No GAIN: Need for Prudent
Antimicrobial Use Provisions to Complement the
GAIN Act
Kevin Outterson
Boston University School of Law
Follow this and additional works at: https://scholarship.law.bu.edu/faculty_scholarship
Part of the Health Law and Policy Commons
This Article is brought to you for free and open access by Scholarly
Commons at Boston University School of Law. It has been accepted for
inclusion in Faculty Scholarship by an authorized administrator of
Scholarly Commons at Boston University School of Law. For more
information, please contact lawlessa@bu.edu.
Recommended Citation
Kevin Outterson, All Pain, No GAIN: Need for Prudent Antimicrobial Use Provisions to Complement the GAIN Act, 30 APUA Clinical
Newsletter 13 (2012).
Available at: https://scholarship.law.bu.edu/faculty_scholarship/94
















































No. 1, p. 13
















Electronic copy available at: http://ssrn.com/abstract=2071244
OUTTERSON 
13 
All pain, no GAIN: need for prudent 
antimicrobial use provisions to complement 
the GAIN Act 
Kevin Outterson, J.D. 
 
Associate Professor of Law & Director of the Health Law Program, Boston University; Editor in Chief, Journal 
of Law, Medicine & Ethics 
The development of new antibiotics without hav-
ing mechanisms to insure their appropriate use is much 
like supplying your alcoholic patients with a finer bran-
dy.  (Dennis Maki, IDSA meeting, 1998 [1, 2]) 
 
Only one health care bill is likely to pass Con-
gress in this election year:  the Prescription Drug User 
Fee Act V (PDUFA V).  Every five years, the FDA and 
the drug and device industries renegotiate the user fees 
and regulatory priorities for the FDA.  PDUFA V is the 
fifth generation in this process.  This bill is very likely to 
pass Congress this summer because many jobs at the 
FDA are no longer funded from general federal appropri-
ations, but come from these user fees.  If the bill doesn’t 
pass, many people at the FDA will be furloughed or fired.   
Since it is a “must pass” bill with bipartisan sup-
port, PDUFA V has attracted additional provisions, hop-
ing to hitch a ride and thus become law.  The Generating 
Antibiotic Incentives Now (GAIN) Act is one prominent 
example.  The GAIN Act is prominently featured in both 
the House and Senate versions of PDUFA V. 
The stated objectives of the GAIN Act include 
increased surveillance of resistant bacteria, more respon-
sible use of existing antibiotics, and increased incentives 
to develop new antibiotics. However, the current draft of 
the GAIN Act does not provide any binding requirements 
to implement antimicrobial stewardship, appropriate use, 
and conservation.  It focuses exclusively on bringing new 
antibiotics to market quickly, without any changes what-
soever to patterns of use in either human or animal popu-
lations.  More brandy for the alcoholics. 
It didn’t start out this way.  The Infectious Dis-
eases Society of America (IDSA) testified before Con-
gress on March 8, 2012, and asked for both “strong in-
centives to spur new anti-infective research and develop-
ment (R&D) and promote antimicrobial steward-
ship.”  [3] While the IDSA’s primary focus has long been 
on promoting new antimicrobial drugs, this testimony 
notably included many proposals (advocated by public 
health organizations such as APUA) for preserving and 
extending the useful life of existing treatments as well.  
They suggested creating a new regulatory pathway for 
“special purpose limited medical use drugs” which would 
be strictly limited to appropriate antimicrobial use.  IDSA 
called for payors to take a more active role in appropriate 
use and value-based reimbursement for diagnostics.  ID-
SA called for implementation of effective antimicrobial 
stewardship programs as a condition of participation in 
Medicare and Medicaid.  IDSA also specifically recom-
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mended a robust surveillance system to “promote meas-
urement of antibiotic usage across all health care settings 
and support adoption and implementation of comprehen-
sive antimicrobial stewardship programs across all health 
care settings to promote the appropriate use of antibiot-
ics.”  Finally, they suggested that drug companies devel-
op a plan for educating health care providers on the ap-
propriate use of new antibiotics and “to reinforce precau-
tions to reduce the risk of resistance.” 
As of late April 2012, none of these provisions 
are included in the latest House or Senate versions.  What 
has survived is an entirely one-sided emphasis on bring-
ing new antibiotics to market quick-
ly, even if the safety data is less 
complete and without regard to ap-
propriate use.  The GAIN Act will 
add 5 or more years of data exclu-
sivity on to the end of patent terms 
for “qualified infectious disease 
products,” extending the effective 
patent period by about 40%, from 12 
to 17 years.  In economic terms, these extensions in ef-
fective patent life will eventually cost the US health care 
system several billion dollars in prescription drug expens-
es due to the delayed introduction of generic antibiotics.  
But, in a perfect Washington game, these expenses will 
not count against the GAIN Act when the Congressional 
Budget Office scores the bill.  As the IDSA testimony 
points out: “IDSA’s exclusivity proposals will likely not 
score a cost to the federal government for the next decade 
or two, given the average amount of patent life typically 
remaining on new antibiotics at the time they are ap-
proved.  Major companies, including GlaxoSmithKline 
(GSK) and Pfizer, agree with IDSA’s assessment.”       
In addition to the IDSA testimony, in early April 
2012, several stewardship proposals were made to con-
gressional staff during bipartisan discussions on the 
GAIN Act.  One proposal was to limit the new GAIN 
incentives to companies that met appropriate use or stew-
ardship targets set by the FDA.  In other words, the feder-
al government would agree to spend billions to bring new 
antibiotics to market, but only if the companies were 
careful with how they were used.  Another proposal 
called for the Centers for Disease Control and Prevention 
(CDC) to spend $10 million per year in surveillance, to 
track the resistance profiles of the new drugs approved 
under GAIN.  Neither proposal made the cut.  The only 
amendment that might be considered friendly to appropri-
ate use is proposed section 906 of the Senate bill, which 
calls for a study by the National Academies on alternative 
business models for antimicrobial R&D, including prize 
funds. [4-5]  
At this point, public health would be better 
served if GAIN did not pass as part of PDUFA V.  Any 
new incentives for rushing antibiotics to market must be 
matched by similar commitments to 
stewardship and appropriate use.  [6-
7] Value-based reimbursement of 
both antibiotics and companion diag-
nostics should include strong support 
for appropriate use.  [8-9] Otherwise, 
we might succeed at meeting the 
IDSA’s goal of 10 new drugs by 
2020, but fail in the ultimate goal of 
having effective antimicrobials at the moment of need 
due to accelerating resistance. [10] 
The correct policy isn’t simply conservation or 
new production; we need both, in a balanced approach.  
As currently drafted, GAIN is not balanced, but this 
could be corrected this summer in the Conference Com-
mittee before Congress passes PDUFA V. 
 
Professor Outterson is an appointed member of 
the Antimicrobial Resistance Working Group of the OID/
Board of Scientific Counselors, CDC and a faculty asso-
ciate at the Harvard Center for Communicable Disease 
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